Browse the corpus

Outcomes over the first two years of treatment with mepolizumab in severe asthma. Almost a third of our patients with severe asthma did not have continued benefit from mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.